EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies

Kumudesh Mishra iD, Nadin Khatib, Dinorah Barasch iD, Pradeep Kumar, Sharon Garti, Nissim Garti, Or Kakhlon iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147861 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kumudesh Mishra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem 9112001, Israel. Hauptthemen laut MEDLINE: Xanthophylls, Antioxidants, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, Lyotropic Delivery Systems (LDS) Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Astaxanthin (ATX) is a carotenoid nutraceutical with poor bioavailability due to its high lipophilicity. We tested a new tailored nanodroplet capable of solubilizing ATX in an oil-in-water micro-environment (LDS-ATX) for its capacity to improve the ATX pharmacokinetic profile and therapeutic efficacy. We used liquid chromatography tandem mass spectrometry (LC-MS/MS) to profile the pharmacokinetics of ATX and LDS-ATX, superoxide mutase (SOD) activity to determine their antioxidant capacity, protein carbonylation and lipid peroxidation to compare their basal and lipopolysaccharide (LPS)-induced oxidative damage, and ELISA-based detection of IL-2 and IFN-γ to determine their anti-inflammatory capacity. ATX and LDS-ATX corrected only LPS-induced SOD inhibition and oxidative damage. SOD activity was restored only by LDS-ATX in the liver and brain and by both ATX and LDS-ATX in muscle. While in the liver and muscle, LDS-ATX attenuated oxidative damage to proteins and lipids better than ATX; only oxidative damage to lipids was preferably corrected by LDS-ATX in the brain. IL-2 and IFN-γ pro-inflammatory response was corrected by LDS-ATX and not ATX in the liver and brain, but in muscle, the IL-2 response was not corrected and the IFN-γ response was mitigated by both. These results strongly suggest an organ-dependent improvement of ATX bioavailability and efficacy by the LDS-ATX nanoformulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

XanthophyllsAntioxidantsAnti-Inflammatory AgentsAnimalsMiceOxidative StressMaleNanoparticlesTandem Mass SpectrometryLiverDrug CarriersLipid PeroxidationSuperoxide DismutaseLipopolysaccharidesInterferon-gamma

Stichwörter der Autor:innen

astaxanthinnanodroplet formulationsoxidative damage

Substanzen

XanthophyllsastaxanthineAntioxidantsAnti-Inflammatory AgentsDrug CarriersSuperoxide DismutaseLipopolysaccharidesInterferon-gamma

Autor:innen und Institutionen

  • Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem 9112001, Israel.
  • Lyotropic Delivery Systems Ltd., Hi-Tech Park, Row 5(1), Edmond J. Safra Campus, Jerusalem 9139002, Israel.
  • Mass Spectrometry Unit, Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
  • Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9112001, Israel.

ORCID-Profile: Kumudesh Mishra, Dinorah Barasch, Or Kakhlon

Förderung

  • CSRD VA
  • Lyotropic Delivery Systems (LDS) Ltd.

Zitieren

APA

Mishra, K., Khatib, N., Barasch, D., Kumar, P., Garti, S., Garti, N., & Kakhlon, O. (2024). A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147861

Vancouver

Mishra K, Khatib N, Barasch D, Kumar P, Garti S, Garti N, et al. A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147861

BibTeX
@article{Mishra2024,
  author = {Mishra, Kumudesh and Khatib, Nadin and Barasch, Dinorah and Kumar, Pradeep and Garti, Sharon and Garti, Nissim and Kakhlon, Or},
  title = {A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147861}
}
Kostenlos starten →